Coronavirus disease 2019 (COVID-19), first recognized in Wuhan, China, was recently declared a global pandemic by the World Health Organization (WHO). Advanced age and comorbid disease, well-known characteristics in the solid tumor population, have been reported as risk factors for severe disease and death. Cancer-related immunosuppression and its treatments also seem to play an active role in the prognosis, response, and clinical outcomes of these patients. The most effective combination therapy for COVID-19 is still under investigation, and the use of corticosteroids is controversial. Although, as a group, metastatic cancer patients are often considered not to be good candidates for ICU treatment, the individual prognosis should always come into consideration, even in a context of high pressure on medical facilities. We report the case of a stage IV prostate cancer patient infected with SARS-CoV-2 who required ICU admission and recovered from COVID-19 infection. Further studies are needed in order to identify accurate clinical prognostic criteria and provide the best treatment for these challenging patients.
Keywords
COVID-19, SARS-CoV-2, Cancer, Critical care, Treatment Outcome
References
World Health Organization (WHO).
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Vol.1-2. Geneva: WHO; 2020. p. 1-21.
LiangW, GuanW, ChenR, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
Rodriguez-MoralesA, Cardona-OspinaJ, Gutiérrez-OcampoE, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis.
Doença pelo novo Coronavírus (COVID-19) – Nova definição de caso. Lisboa: DGS; 2020. Orientação 02/2020 atualizada em 09/03/2020.
ZhangL, ZhuF, XieL, et al.Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.
SchellongowskiP, SperrWR, WohlfarthP, et al. Critically ill patients with cancer: chances and limitations of intensive care medicine — a narrative review.
WuC, ChenX, CaiY, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
GautretP, LagierJ-C, ParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
SheahanTP, SimsAC, LeistSR, et al.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
MendesJJ, MergulhãoP, FroesF, PaivaJA, GouveiaJ. Recommendations from the Sociedade Portuguesa de Cuidados Intensivos and Infection & Sepsis Group for intensive care approach to COVID-19.
Rev Bras Ter Intensiva. 2020;32(1):2-10. [PMID:32401989]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email